Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganitumab + panitumumab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of ganitumab, a fully human monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), and panitumumab, a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR). This combination targets multiple growth factor pathways simultaneously, potentially providing enhanced anti-tumor activity in certain cancer types.
- Brand names
- Vectibix (panitumumab)
02
Targets
EGFR (Epidermal growth factor receptor)IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on ganitumab + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganitumab + panitumumab.